VCEL Stock Overview
A commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for VCEL from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Vericel Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$41.07 |
| 52 Week High | US$63.00 |
| 52 Week Low | US$37.39 |
| Beta | 1.32 |
| 1 Month Change | 0.49% |
| 3 Month Change | -24.38% |
| 1 Year Change | -18.40% |
| 3 Year Change | 52.51% |
| 5 Year Change | 187.00% |
| Change since IPO | -96.33% |
Recent News & Updates
Risks To Shareholder Returns Are Elevated At These Prices For Vericel Corporation (NASDAQ:VCEL)
May 01
Vericel: Scalable Growth With Strong Margins
Mar 06Recent updates
Risks To Shareholder Returns Are Elevated At These Prices For Vericel Corporation (NASDAQ:VCEL)
May 01Vericel: Scalable Growth With Strong Margins
Mar 06Vericel Corporation: Hard To Justify Current Valuation
Dec 19Vericel Corporation (NASDAQ:VCEL) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected
Nov 09
MACI And NexoBrid Drive Record Revenues And Profit Growth, Setting Stage For Robust Future Performance
Expansion of MACI and NexoBrid markets driving record revenues, indicating significant future revenue growth.What Vericel Corporation's (NASDAQ:VCEL) P/S Is Not Telling You
Jul 12Vericel Corporation (NASDAQ:VCEL) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 11It's Unlikely That The CEO Of Vericel Corporation (NASDAQ:VCEL) Will See A Huge Pay Rise This Year
Apr 26Is There An Opportunity With Vericel Corporation's (NASDAQ:VCEL) 49% Undervaluation?
Mar 02Revenues Not Telling The Story For Vericel Corporation (NASDAQ:VCEL) After Shares Rise 29%
Feb 02Vericel Corporation's (NASDAQ:VCEL) Shareholders Might Be Looking For Exit
May 05Vericel Corporation: Stock Has Fallen, But Not Enough To Make This A Buy
Oct 10Vericel Q2 2022 Earnings Preview
Aug 02Calculating The Fair Value Of Vericel Corporation (NASDAQ:VCEL)
Apr 19Vericel - A Disruptive Business With Years Of Growth Remaining
Apr 12Vericel: In The Middle Of Difficulty Is An Opportunity
Dec 31Shareholder Returns
| VCEL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.9% | 5.1% | -1.1% |
| 1Y | -18.4% | -14.9% | 9.1% |
Return vs Industry: VCEL underperformed the US Biotechs industry which returned -11.6% over the past year.
Return vs Market: VCEL underperformed the US Market which returned 11.1% over the past year.
Price Volatility
| VCEL volatility | |
|---|---|
| VCEL Average Weekly Movement | 7.6% |
| Biotechs Industry Average Movement | 12.0% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: VCEL has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: VCEL's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 357 | Nick Colangelo | www.vcel.com |
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014.
Vericel Corporation Fundamentals Summary
| VCEL fundamental statistics | |
|---|---|
| Market cap | US$2.19b |
| Earnings (TTM) | US$2.98m |
| Revenue (TTM) | US$238.54m |
Is VCEL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VCEL income statement (TTM) | |
|---|---|
| Revenue | US$238.54m |
| Cost of Revenue | US$65.52m |
| Gross Profit | US$173.03m |
| Other Expenses | US$170.05m |
| Earnings | US$2.98m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.059 |
| Gross Margin | 72.54% |
| Net Profit Margin | 1.25% |
| Debt/Equity Ratio | 0% |
How did VCEL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/21 06:27 |
| End of Day Share Price | 2025/05/21 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vericel Corporation is covered by 22 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Keay Nakae | Ascendiant Capital Markets LLC |
| Michael Gorman | BTIG |
| Caitlin Cronin | Canaccord Genuity |